% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Poorebrahim:144380,
      author       = {M. Poorebrahim and S. Sadeghi and E. Fakhr$^*$ and M. F.
                      Abazari and V. Poortahmasebi and A. Kheirollahi and H.
                      Askari and A. Rajabzadeh and M. Rastegarpanah and A. Linē
                      and A. Cid-Arregui$^*$},
      title        = {{P}roduction of {CAR} {T}-cells by {GMP}-grade lentiviral
                      vectors: {L}atest advances and future prospects.},
      journal      = {Critical reviews in clinical laboratory sciences},
      volume       = {nn},
      issn         = {1549-781X},
      address      = {London},
      publisher    = {Informa Healthcare56466},
      reportid     = {DKFZ-2019-01833},
      pages        = {1 - 27},
      year         = {2019},
      abstract     = {Chimeric antigen receptor (CAR) T-cells represent a
                      paradigm shift in cancer immunotherapy and a new milestone
                      in the history of oncology. In 2017, the Food and Drug
                      Administration approved two CD19-targeted CAR T-cell
                      therapies (Kymriah™, Novartis, and Yescarta™, Kite
                      Pharma/Gilead Sciences) that have remarkable efficacy in
                      some B-cell malignancies. The CAR approach is currently
                      being evaluated in multiple pivotal trials designed for the
                      immunotherapy of hematological malignancies as well as solid
                      tumors. To generate CAR T-cells ex vivo, lentiviral vectors
                      (LVs) are particularly appealing due to their ability to
                      stably integrate relatively large DNA inserts, and to
                      efficiently transduce both dividing and nondividing cells.
                      This review discusses the latest advances and challenges in
                      the design and production of CAR T-cells, and the good
                      manufacturing practices (GMP)-grade production process of
                      LVs used as a gene transfer vehicle. New developments in the
                      application of CAR T-cell therapy are also outlined with
                      particular emphasis on next-generation allogeneic CAR
                      T-cells.},
      subtyp        = {Review Article},
      cin          = {D015 / D122},
      ddc          = {570},
      cid          = {I:(DE-He78)D015-20160331 / I:(DE-He78)D122-20160331},
      pnm          = {314 - Tumor immunology (POF3-314)},
      pid          = {G:(DE-HGF)POF3-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31314617},
      doi          = {10.1080/10408363.2019.1633512},
      url          = {https://inrepo02.dkfz.de/record/144380},
}